Alnylam Pharmaceuticals, Inc.
ALNY
$438.93
$3.830.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 773.69M | 594.19M | 593.17M | 500.92M | 659.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 773.69M | 594.19M | 593.17M | 500.92M | 659.83M |
| Cost of Revenue | 142.95M | 71.04M | 102.82M | 85.91M | 68.67M |
| Gross Profit | 630.74M | 523.15M | 490.35M | 415.01M | 591.15M |
| SG&A Expenses | 323.31M | 239.95M | 295.34M | 220.99M | 248.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 789.89M | 576.11M | 698.33M | 577.82M | 611.21M |
| Operating Income | -16.20M | 18.08M | -105.16M | -76.91M | 48.61M |
| Income Before Tax | -35.36M | -41.60M | -193.96M | -108.66M | -11.17M |
| Income Tax Expenses | 30.92M | 15.88M | -110.20M | 2.91M | 5.72M |
| Earnings from Continuing Operations | -66.28M | -57.48M | -83.76M | -111.57M | -16.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.28M | -57.48M | -83.76M | -111.57M | -16.89M |
| EBIT | -16.20M | 18.08M | -105.16M | -76.91M | 48.61M |
| EBITDA | -2.26M | 32.48M | -90.99M | -62.92M | 63.62M |
| EPS Basic | -0.51 | -0.44 | -0.65 | -0.87 | -0.13 |
| Normalized Basic EPS | -0.16 | -0.20 | -0.94 | -0.52 | -0.05 |
| EPS Diluted | -0.51 | -0.44 | -0.65 | -0.87 | -0.13 |
| Normalized Diluted EPS | -0.16 | -0.20 | -0.94 | -0.52 | -0.05 |
| Average Basic Shares Outstanding | 130.63M | 129.68M | 129.12M | 128.59M | 126.73M |
| Average Diluted Shares Outstanding | 130.63M | 129.68M | 129.12M | 128.59M | 126.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |